Abbonarsi

External validation and update of the early detection rule for severe hyperkalemia among patients with symptomatic bradycardia - 09/12/21

Doi : 10.1016/j.ajem.2021.03.007 
Dong Han Kim, MD a, Sung-Bin Chon, MD, MSc a, , Ji Hun Choi, BS b, Young Ho Kwak, MD, PhD c
a Department of Emergency Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Republic of Korea 
b CHA University School of Medicine, Pocheon 11160, Republic of Korea 
c Department of Emergency Medicine, Seoul National University School of Medicine, Seoul 03080, Republic of Korea 

Corresponding author at: Department of Emergency Medicine, CHA Bundang Medical Center, CHA University School of Medicine, 59, Yatap-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea.Department of Emergency MedicineCHA Bundang Medical CenterCHA University School of Medicine59, Yatap-ro, Bundang-guSeongnam-siGyeonggi-doRepublic of Korea

Abstract

Objective

Chon et al. suggested a high prevalence of severe hyperkalemia (serum potassium ≥ 6.0 mEq/L with electrocardiographic [ECG] changes) among patients with symptomatic or extreme bradycardia. Despite the urgent need to detect and treat severe hyperkalemia, serum potassium result may be available too late and is often spuriously high. Meanwhile, the traditional, descriptive ECG findings of severe hyperkalemia have shown unsatisfactory diagnostic powers. To overcome these diagnostic problems, they outlined the following quantitative rules to facilitate its early detection: Maximum precordial T wave ≥ 8.5 mV (2), atrial fibrillation/junctional bradycardia (1), heart rate (HR) ≤ 42/min (1) with (original rule)/without (ECG-only rule) diltiazem medication (2), and diabetes mellitus (1). Here we report on our external validation of these rules and the resulting updates.

Methods

This retrospective, cross-sectional study included all adults with symptomatic (HR ≤ 50/min with syncope/pre-syncope/dizziness, altered mentality, chest pain, dyspnea, general weakness, oliguria, or shock) or extreme (HR ≤ 40/min) bradycardia who visited a university emergency department from 2014 to 2019. After validating the abovementioned rules externally, we selected risk factors of severe hyperkalemia among the ECG findings and easy-to-assess clinical variables by multiple logistic regression analysis. After modelling the updated ‘ECG-only’ and ‘ECG-plus’ indices, we internally validated the better of the two by bootstrapping with 1000 iterations.

Results

Among 455 symptomatic/extreme bradycardia cases (70.3 ± 13.1 years; 213 females [46.8%]), 70 (15.4%) had severe hyperkalemia. The previous ECG-only rule showed a c-statistic of 0.765 (95% CI: 0.706–0.825), Hosmer-Lemeshow test of p < 0.001, and a calibration slope of 0.719 (95% CI: 0.401–1.04). On updating, the ECG-plus index summing junctional bradycardia/atrial fibrillation (1), maximum precordial T wave≥8.0 mV (2), general weakness as the chief complaint (2), oxygen demand (1), and dialysis (2) outperformed the ECG-only index (c-statistic, 0.832; 95% CI, 0.785–0.880 vs. 0.764; 95% CI, 0.700–0.828; p = 0.011). On bootstrapping, the c-statistic was 0.832 (95% CI: 0.786–0.878). For scores ≥ 3 (positive likelihood ratio ≥ 5.0), the sensitivity and specificity were 0.514 and 0.901, respectively. For scores ≤ 1, negative likelihood ratio was ≤0.2.

Conclusions

Previous rules showed less satisfactory calibration but fair discrimination to detect severe hyperkalemia in patients with symptomatic or extreme bradycardia. We propose the ECG-plus index as the optimum tool to facilitate its early detection.

Il testo completo di questo articolo è disponibile in PDF.

Highlights

Severe hyperkalemia is common among patients with symptomatic or extreme bradycardia.
A suggested rule summed max. precordial T wave≥8.5mV(2), atrial fibrillation[AF]/junctional bradycardia[JB](1) and HR≤42/min(1).
In this study, we externally validated it; it showed less satisfactory calibration but fair discrimination.
We modelled and internally validated an ‘ECG-plus index’ as an updated rule.
It summed max. precordial T wave≥8.0mV(2), AF/JB(1); general weakness as a chief complaint(2), dialysis(2) and O2 demand(1).

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Bradycardia, Electrocardiography, Hyperkalemia, Sensitivity and specificity, Validation study


Mappa


© 2021  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 51

P. 401-408 - Gennaio 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Point of Care Ultrasound in the Diagnosis of Necrotizing Fasciitis
  • Shadi Lahham, Inna Shniter, Monica Desai, Rana Andary, Soheil Saadat, John C. Fox, Scott Pierce
| Articolo seguente Articolo seguente
  • Efficacy and safety of tolvaptan in acute heart failure patients during long-distance transportation
  • Shuko Iwata, Masaru Yamaki, Takeshi Nishiura, Keita Nakagawa, Shota Tokuno, Hirotsuka Sakai, Motoi Okada

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.